Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Minority Interest (2020 - 2025)

Historic Minority Interest for ImmunityBio (IBRX) over the last 6 years, with Q3 2025 value amounting to $909000.0.

  • ImmunityBio's Minority Interest fell 780.93% to $909000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $909000.0, marking a year-over-year decrease of 780.93%. This contributed to the annual value of $969000.0 for FY2024, which is 771.43% down from last year.
  • Per ImmunityBio's latest filing, its Minority Interest stood at $909000.0 for Q3 2025, which was down 780.93% from $930000.0 recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Minority Interest registered a high of $1.1 million during Q3 2023, and its lowest value of -$3.1 million during Q2 2023.
  • For the 5-year period, ImmunityBio's Minority Interest averaged around -$485473.7, with its median value being $451000.0 (2021).
  • Its Minority Interest has fluctuated over the past 5 years, first plummeted by 52394.68% in 2022, then surged by 14500.42% in 2023.
  • ImmunityBio's Minority Interest (Quarter) stood at -$1.7 million in 2021, then tumbled by 43.28% to -$2.5 million in 2022, then skyrocketed by 142.12% to $1.0 million in 2023, then fell by 7.71% to $969000.0 in 2024, then decreased by 6.19% to $909000.0 in 2025.
  • Its Minority Interest stands at $909000.0 for Q3 2025, versus $930000.0 for Q2 2025 and $949000.0 for Q1 2025.